Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease

BACKGROUND: Monoclonal antibodies inhibiting tumour necrosis factor-α (TNFα) signalling pathway (anti-TNFα) have been widely used in Crohn’s disease (CD). However, treatment response varies among patients with CD and the clinical outcome is dependent on single nucleotide polymorphisms (SNP) in TNFα...

Descripción completa

Detalles Bibliográficos
Autores principales: Qasem, Ahmad, Ramesh, Seela, Naser, Saleh A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361334/
https://www.ncbi.nlm.nih.gov/pubmed/30815272
http://dx.doi.org/10.1136/bmjgast-2018-000246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361334/
https://www.ncbi.nlm.nih.gov/pubmed/30815272
http://dx.doi.org/10.1136/bmjgast-2018-000246

Ejemplares similares